Drug intelligence / Profile preview

ORYN1064

Development stage: Preclinical
Lead developer: Oryn Therapeutics
Modality: Peptides
Administration: Oral

Overview

ORYN1064 is a preclinical-stage, orally administered macrocyclic peptide developed by Oryn Therapeutics for the treatment of inflammatory and autoimmune diseases. As a next-generation candidate within the company's Orynotide platform, ORYN1064 is designed to modulate allosteric control points on proteins that regulate inflammatory and tissue-remodeling pathways. The program incorporates pharmacological and dosing insights gained from Oryn's lead candidate, ORTD-1, which was evaluated in healthy volunteers and patients with rheumatoid arthritis. ORYN1064 is specifically formulated for once-daily (QD) oral administration, aiming to provide a potent and convenient therapeutic option for chronic inflammatory conditions.

Beyond the preview

Go deeper on ORYN1064.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORYN1064.

Explore the full profile